RxDoctor Payments Data

Bridget Walters

Family · Ocilla, GANPI 1669880456

Payments from drug & device makers

$2,131in general payments, 2019–2025

Across 107 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$546
  • AstraZeneca$484
  • GSK$206
  • Astellas Pharma US Inc$181
  • AbbVie$117
  • Boehringer Ingelheim$109
  • plus $488 from 13 others

What the payments were for

  • Food & beverage$2,03796%
  • Education$944%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,131 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$53,057
Medicare patients
208
Services billed
1,341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide138$178,276
JardianceEmpagliflozin158$143,204
FarxigaDapagliflozin Propanediol146$124,606
MounjaroTirzepatide81$98,320
EliquisApixaban110$85,372
TrulicityDulaglutide53$64,851
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$53,958
MyrbetriqMirabegron72$49,356
LinzessLinaclotide57$46,919
JanuviaSitagliptin Phosphate53$37,789
RybelsusSemaglutide17$22,791
VascepaIcosapent Ethyl43$18,636
Tresiba Flextouch U-100Insulin Degludec35$17,703
XareltoRivaroxaban12$12,276
BrilintaTicagrelor19$11,837

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$546$201,067155 claims
Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30$107$164,762149 claims
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere$484$144,398176 claims
Boehringer IngelheimJardiance$109$143,204158 claims
PfizerEliquis$15$85,372110 claims
GSKTrelegy Ellipta$206$53,95861 claims
Astellas Pharma US IncMyrbetriq$181$49,35672 claims
AbbVieLinzess$117$46,91957 claims
Johnson & JohnsonXarelto$29$12,27612 claims
Sanofi-aventis U.S. LLCLantus$29$3,58537 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Ocilla

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →